Compare Ford Motor Company (F) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs Organon & Co. Common Stock — how do they compare? Ford Motor Company trades at $12 (market cap $48.25B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Ford Motor Company is far larger — about 13.3× Organon & Co. Common Stock's market cap, and Ford Motor Company pays the higher dividend (4.96%). Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 105 Days and Organon & Co. Common Stock for 0 Days on average.
| F | OGN | |
|---|---|---|
Market Cap | $48.25B | $3.62B |
Volume | 33,627,673 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $13.81 |
52-Week Low | $11.21 | $5.70 |
Typical Hold Time | 105 Days | 0 Days |
Enterprise Value | $180.21B | $11.04B |
Dividend Yield | 4.96% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.05, up 0.42% on the day, with a mixed technical picture showing bearish moving averages but oversold RSI conditions. Fundamentally, the company reported a net loss of $8.18 billion in 2025 despite $187.27 billion revenue, with negative profit margins and declining sales trends. Recent news highlights supplier disruptions affecting F-150 production and a 6.6% Q3 sales decline, though the company maintains its No. 3 U.S. market position.
Ford faces significant challenges with negative profitability and competitive pressures, though analyst consensus suggests 31% upside to the $15.79 price target. The stock presents a value opportunity given low P/S and P/B ratios, but investors must weigh operational headwinds against the company's strong commercial division and ongoing hybrid vehicle transition.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
